Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a first-in-class oral ITK inhibitor for T-cell lymphomas and inflammatory diseases, alongside adenosine-pathway oncology assets, with no product revenue and a cash runway into Q2 2028.
- Company typePublic
- Founded2014
- HeadquartersBurlingame, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Corvus Pharmaceuticals does
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with 51–100 employees. The company is developing a pipeline of investigational immunotherapies for cancer and immune-mediated diseases, anchored by soquelitinib (CPI-818), a first-in-class oral small molecule that selectively inhibits interleukin-2-inducible T-cell kinase (ITK). ITK inhibition modulates T-cell differentiation, skewing responses toward Th1 helper cells while suppressing Th2 and Th17 pathways. The pipeline also includes ciforadenant (CPI-444), an oral adenosine A2a receptor antagonist designed to block immunosuppressive signaling in the tumor microenvironment, and mupadolimab (CPI-006), an anti-CD73 antibody that reduces adenosine production while activating B cells.
Soquelitinib is being evaluated across a broad set of indications: a Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma, Phase 2 trials in atopic dermatitis, asthma, and hidradenitis suppurativa, and combination work in renal cell carcinoma. Phase 1 atopic dermatitis data have shown 75% EASI-75 response rates, a 72% mean EASI reduction versus 40% for placebo, and no rebound during drug-free follow-up up to 90 days. Corvus holds a 49% equity stake in Angel Pharmaceuticals, a China-focused joint venture co-founded in 2020 that is running parallel atopic dermatitis and asthma trials in China.
The company is pre-revenue and has generated no product sales through fiscal 2025. Capital is raised through public equity markets; in January 2026 Corvus closed a $201.2 million upsized underwritten offering (led by Jefferies and Goldman Sachs), bringing cash and marketable securities to approximately $236.7 million at the end of Q1 2026 and extending the runway into Q2 2028. R&D expenses were $33.7 million in FY2025. Revenue, when it materializes, will come from prescription drug sales, supplemented by potential royalties or milestones from the Angel Pharmaceuticals partnership.
Corvus Pharmaceuticals firmographics
Firmographics- Name
- Corvus Pharmaceuticals
- Legal name
- Corvus Pharmaceuticals, Inc.
- Website
- https://corvuspharma.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a first-in-class oral ITK inhibitor for T-cell lymphomas and inflammatory diseases, alongside adenosine-pathway oncology assets, with no product revenue and a cash runway into Q2 2028.
- Ownership category
- akta.pro rank
Corvus Pharmaceuticals industry classification
Industry- Product category
- Clinical-stage Immuno-oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where Corvus Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Burlingame
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Corvus Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Product Revenue: Currently pre-revenue clinical-stage company. No commercialized products. Revenue will come from drug sales upon regulatory approval.
- Licensing/Partnership Revenue: Potential future revenue from licensing agreements, such as partnership with Angel Pharmaceuticals for development in China.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Corvus Pharmaceuticals product offering
Product offeringCore offering
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational small-molecule and antibody immunotherapies that modulate T-cell signaling and the adenosine pathway for the treatment of immune diseases and cancer. Its lead asset, soquelitinib (CPI-818), is a first-in-class oral selective ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, supported by ciforadenant (CPI-444), an oral A2a receptor antagonist, and mupadolimab (CPI-006), an anti-CD73 antibody.
Product overview
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of investigational medicines for immune diseases and cancer. The company's core portfolio consists of three clinical-stage programs: soquelitinib (CPI-818), an oral ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis; ciforadenant (CPI-444), an oral A2a receptor antagonist checkpoint inhibitor; and mupadolimab (CPI-006), an anti-CD73 antibody. Soquelitinib is the lead program, a first-in-class selective ITK inhibitor that modulates T cell signaling pathways. The other two programs target the adenosine pathway through different mechanisms. The company also has a partnership with Angel Pharmaceuticals for development in China.
Differentiator
Problem solved
Functional benefit
Brands
- Soquelitinib (CPI-818): Lead product candidate - first-in-class, oral therapy that selectively inhibits ITK to modulate and control parallel signaling pathways in the immune system
- Ciforadenant (CPI-444)
- Mupadolimab (CPI-006)
Products and services
- Soquelitinib (CPI-818) Investigational first-in-class oral small molecule that selectively inhibits ITK (interleukin-2-inducible T cell kinase), affecting T cell differentiation by inducing Th1 helper cells while blocking Th2 and Th17 cells. Being developed for T-cell lymphomas, atopic dermatitis, asthma, and hidradenitis suppurativa.
- Ciforadenant (CPI-444) Investigational small molecule, oral checkpoint inhibitor designed to block adenosine binding to immune cells in the tumor microenvironment by targeting the A2a receptor, disabling tumors' ability to subvert immune attack.
- Mupadolimab (CPI-006) Investigational anti-CD73 antibody that blocks adenosine production in the tumor microenvironment and binds to B cells, activating and differentiating them into antibody-producing plasma cells, augmenting both cellular and humoral immunity.
Quantifiable outcome
- 75% of patients achieved EASI 75 in Phase 1 atopic dermatitis trial (cohort 4)
- +2 more outcomes
Companies that use Corvus Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
Corvus Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Corvus Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Angel Pharmaceuticals Ltd.coreCorvus co-founded Angel Pharma in 2020 and holds 49% equity stake. Angel Pharma is conducting Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial for asthma in China. Initial atopic dermatitis results expected late 2026, asthma trial launching early 2027. Corvus invested $5 million in June 2026 $13.5M financing round.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Corvus Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Arcus Biosciences: Clinical-stage oncology company developing small-molecule and antibody programs against the adenosine pathway (CD73, A2a receptor), directly overlapping with Corvus's ciforadenant and mupadolimab programs in mechanism and indication.
- Innate Pharma: Clinical-stage immunology company developing adenosine-pathway and innate-immune targeted antibodies and NK-cell engagers, with overlap to Corvus's adenosine-pathway strategy and T-cell-directed immunomodulation pipeline.
- Compugen: Computational-immunology biotech developing novel immuno-oncology targets for cancer, with a therapeutic focus area and clinical-stage pipeline that overlaps Corvus's tumor-microenvironment-directed approach.
- Surface Oncology: Clinical-stage immuno-oncology company focused on targeting the tumor microenvironment via novel mechanisms, including myeloid and T-cell modulators, broadly comparable to Corvus's adenosine-pathway and ITK programs.
Emerging players
- Werewolf Therapeutics: Clinical-stage biotech developing tumor-activated immunotherapies including T-cell engagers and INDUCER molecules, comparable to Corvus as a small-cap, oncology-focused immunotherapy developer with selective mechanism-based assets.
- Keros Therapeutics: Clinical-stage biotech developing small-molecule modulators of the TGF-beta superfamily for hematology and immunology, comparable to Corvus as a focused clinical-stage immunology and inflammation company.
Broad incumbents
- ChemoCentryx (Amgen): Now part of Amgen following acquisition, ChemoCentryx pioneered oral small-molecule inhibitors of complement and chemoattractant receptors for immune diseases — the same 'small molecule replacing injectable biologic' positioning Corvus is pursuing with soquelitinib in atopic dermatitis.
- Regeneron Pharmaceuticals: Markets Dupixent (dupilumab), the dominant injectable biologic in moderate-to-severe atopic dermatitis. As Corvus's soquelitinib targets the same indication with an oral, first-in-class ITK mechanism, Regeneron is the most relevant competitive incumbent.
- AbbVie: Markets Rinvoq (upadacitinib), a leading oral JAK inhibitor in atopic dermatitis, and Skyrizi, providing direct competitive context for Corvus's oral soquelitinib positioning in the same disease.
- Pfizer: Markets Cibinqo (abrocitinib) and multiple other oral JAK inhibitors in atopic dermatitis, establishing the bar for Corvus's soquelitinib oral ITK inhibitor program in this competitive multi-modality indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Corvus Pharmaceuticals social profiles
Digital presenceCorvus Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corvus Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles13 records
Corvus Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Corvus Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corvus Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corvus Pharmaceuticals
What does Corvus Pharmaceuticals do?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational small-molecule and antibody immunotherapies that modulate T-cell signaling and the adenosine pathway for the treatment of immune diseases and cancer. Its lead asset, soquelitinib (CPI-818), is a first-in-class oral selective ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, supported by ciforadenant (CPI-444), an oral A2a receptor antagonist, and mupadolimab (CPI-006), an anti-CD73 antibody.
Is Corvus Pharmaceuticals a public or private company?
Corvus Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Corvus Pharmaceuticals founded?
Corvus Pharmaceuticals was founded in 2014. It employs 51 to 100 people.
Where is Corvus Pharmaceuticals based?
Corvus Pharmaceuticals is headquartered in Burlingame, United States, in the North America region.
How does Corvus Pharmaceuticals make money?
Two revenue lines are on record. Product Revenue is the primary driver. The others are licensing/Partnership Revenue.
Who are Corvus Pharmaceuticals's main competitors?
Direct peers on record are Arcus Biosciences, Innate Pharma, Compugen and Surface Oncology. Emerging players are Werewolf Therapeutics and Keros Therapeutics. Broad incumbents are ChemoCentryx (Amgen), Regeneron Pharmaceuticals, AbbVie and Pfizer.
Does Corvus Pharmaceuticals have an API?
No public API is recorded for Corvus Pharmaceuticals.
What industry is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals's product category is Clinical-stage Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.